

Zhen Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2131463/publications.pdf>

Version: 2024-02-01

25
papers

607
citations

759055

12
h-index

610775

24
g-index

25
all docs

25
docs citations

25
times ranked

657
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacokinetics, mass balance, and metabolism of [¹⁴ C]TPN171, a novel PDE5 inhibitor, in humans for the treatment of pulmonary arterial hypertension. <i>Acta Pharmacologica Sinica</i> , 2023, 44, 221-233.	2.8	6
2	Absorption, distribution, metabolism, and excretion of [¹⁴ C]TPN729 after oral administration to rats. <i>Xenobiotica</i> , 2022, 52, 79-90.	0.5	4
3	TPN171H alleviates pulmonary hypertension via inhibiting inflammation in hypoxia and monocrotaline-induced rats. <i>Vascular Pharmacology</i> , 2022, 145, 107017.	1.0	3
4	Species differences in the CYP3A-catalyzed metabolism of TPN729, a novel PDE5 inhibitor. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 482-490.	2.8	6
5	A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 2947-2959.	2.0	3
6	Sub-anesthetic and anesthetic ketamine produce different long-lasting behavioral phenotypes (24h) in the hippocampus. <i>Neurobiology of Learning and Memory</i> , 2020, 167, 107136.	1.0	20
7	Liquid chromatography-tandem mass spectrometric assay for TPN171 in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 191, 113634.	1.4	1
8	Automated design and optimization of multitarget schizophrenia drug candidates by deep learning. <i>European Journal of Medicinal Chemistry</i> , 2020, 204, 112572.	2.6	25
9	Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 15153-15186.	2.9	20
10	Synthesis and biological investigation of triazolopyridinone derivatives as potential multireceptor atypical antipsychotics. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127027.	1.0	5
11	Continuation of structure-activity relationship study of novel benzamide derivatives as potential antipsychotics. <i>Archiv Der Pharmazie</i> , 2019, 352, 1800306.	2.1	2
12	Characterization of TPN171 metabolism in humans via ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 172, 302-310.	1.4	3
13	Pharmacokinetics-Driven Optimization of 4(3H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 4979-4990.	2.9	25
14	Synthesis and Biological Evaluation of Five-Atom-Linker-Based Arylpiperazine Derivatives with an Atypical Antipsychotic Profile. <i>ChemMedChem</i> , 2019, 14, 2042-2051.	1.6	6
15	Synthesis and biological evaluation of a series of novel pyridinecarboxamides as potential multi-receptor antipsychotic drugs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 606-611.	1.0	8
16	Vesicular glutamate transporter 1 (VGLUT1)-mediated glutamate release and membrane GluA1 activation is involved in the rapid antidepressant-like effects of scopolamine in mice. <i>Neuropharmacology</i> , 2018, 131, 209-222.	2.0	35
17	Essential roles of neuropeptide VGF regulated TrkB/mTOR/BICC1 signaling and phosphorylation of AMPA receptor subunit GluA1 in the rapid antidepressant-like actions of ketamine in mice. <i>Brain Research Bulletin</i> , 2018, 143, 58-65.	1.4	17
18	Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 3141-3147.	1.0	6

#	ARTICLE	IF	CITATIONS
19	Thermodynamic and Structural Characterization of Halogen Bonding in Protein-Ligand Interactions: A Case Study of PDE5 and Its Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 3588-3593.	2.9	37
20	Exploration of the 5-bromopyrimidin-4(3H)-ones as potent inhibitors of PDE5. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 4944-4947.	1.0	9
21	The Selectivity and Potency of the New PDE5 Inhibitor TPN729MA. <i>Journal of Sexual Medicine</i> , 2013, 10, 2790-2797.	0.3	13
22	Design, Synthesis, and Pharmacological Evaluation of Monocyclic Pyrimidinones as Novel Inhibitors of PDE5. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 10540-10550.	2.9	28
23	Utilization of Halogen Bond in Lead Optimization: A Case Study of Rational Design of Potent Phosphodiesterase Type 5 (PDE5) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 5607-5611.	2.9	108
24	2-Phenylquinazolin-4(3H)-one, a class of potent PDE5 inhibitors with high selectivity versus PDE6. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 2777-2779.	1.0	20
25	Plasma-Pooling Methods To Increase Throughput for in Vivo Pharmacokinetic Screening. <i>Journal of Pharmaceutical Sciences</i> , 1998, 87, 901-903.	1.6	197